Pharmaceuticals

KHPG

KHPG released FY2025 Q4 earnings on April 22 After-Market (BJT), actual revenue CNY 961.27 M, actual EPS CNY 0.1405

KHPG released FY2026 Q1 earnings on April 22 During-Market (BJT), actual revenue CNY 1.046 B, actual EPS CNY 0.33

KHPG released FY2025 annual earnings on April 22 After-Market (BJT), actual revenue CNY 4.585 B (forecast CNY 4.919 B), actual EPS CNY 1.26 (forecast CNY 1.44)

KHPG to Release FY2025 Earnings on April 23 After-Market (BJT), Forecast Revenue CNY 4.919 B, EPS CNY 1.44

KHPG to Release FY2026 Q1 Earnings Report on April 23 During-Market BJT

KHPG released FY2025 Q3 earnings on October 28 During-Market (BJT), actual revenue CNY 1.17 B, actual EPS CNY 0.3297

KHPG released FY2025 9 Months earnings on October 28 During-Market (BJT), actual revenue CNY 3.624 B, actual EPS CNY 1.1192

KHPG to Release FY2025 Q3 Earnings Report on October 29 During-Market (BJT)

KHPG released FY2025 Q2 earnings on August 27 Pre-Market (BJT), actual revenue CNY 1.255 B, actual EPS CNY 0.3594

KHPG released FY2025 Semi-Annual Earnings on August 27 Pre-Market (BJT), actual revenue CNY 2.454 B, actual EPS CNY 0.79

KHPG to Release FY2025 Semi-Annual Earnings on August 28, 2025 (BJT)

Kanghong Pharmaceutical Issues Warning Against Fraud

Kanghong Pharma's KH110 in Phase III Clinical Trials

Kontron Pharma's Multiple Drugs Enter Phase III Clinical Trials

Kontron Pharmaceutical Sees Valuation Boost Driven by Innovation

Kontron Biotech Receives Approval for KH813 Clinical Trials

Kanghong Pharmaceutical Obtains Registration Certificate for Lifisit Eye Drops

Kanghong Pharmaceutical Subsidiary Obtains Clinical Trial Approval for Songling Blood Vessel Health Capsules

Konopharma's Subsidiary Receives Approval for KH617 Clinical Trials

Kontron Pharmaceutical Secretary Addresses Gene Therapy and Traditional Chinese Medicine Business

002773

Tianfeng Securities: Initiates "Buy" rating for KHPG with a target price of 51.84 yuan

Zhitong

According to the Zhitong Finance APP, KHPG announced that the company recently received the "Drug Registration Certificate" for Ipatasertib tablets issued by the National Medical Products Administration, approving its registration. The indication for this medication is diabetic neuropathy

KHPG: Ipasitide tablets have obtained a drug registration certificate

KHPG issued a statement on the evening of August 12, stating that recent illegal activities have involved criminals impersonating the company to conduct fraud. The company emphasized that it has not engaged in any sales of investment products and has not authorized any third parties to conduct such sales. KHPG warns against these illegal activities and will report the relevant criminals, reserving the right to pursue legal responsibility

KHPG: Criminals are using the company's name to carry out fraud and other activities

688068

300683

688177

688356

In the morning session, the innovative drug concept strengthened again, with Hotgen rising over 10%, reaching a historical high. Junshi Biosciences and Hongbo Medicine also rose over 10%, while Chenxin Pharmaceutical, KHPG, HITECK, BIO-THERA, and JENKEM followed suit

Hotgen

HITECK

BIO-THERA

JENKEM

The concept of innovative drugs has strengthened again, with Hotgen rising over 10% to reach a new historical high

KHPG announced that its stock price has fluctuated by more than 20% recently, but the company's operations are normal and there have been no significant changes. The company and its controlling shareholders, as well as actual controllers, do not have any undisclosed significant matters

KHPG: Currently, production and business activities are normal, and there are no significant matters that should be disclosed but have not been disclosed

KHPG announced that its wholly-owned subsidiary Chengdu KHPG Biotechnology Co., Ltd. has received approval from the National Medical Products Administration to conduct clinical trials for "KH813 Injection." KH813 Injection is a biosimilar of Pembrolizumab, primarily used for the treatment of various advanced solid tumors, capable of blocking the interaction between PD-1 and PD-L1, PD-L2, thereby enhancing anti-tumor immune response

KHPG: "KH813 Injection" drug clinical trial approved

KHPG announced that the company recently received the drug registration certificate for Lifitegrast Eye Drops issued by the National Medical Products Administration, approving its registration. Lifitegrast Eye Drops are indicated for the treatment of signs and symptoms of dry eye, formulated as an ophthalmic preparation with a specification of 5%. This drug is the first in the country to complete clinical research and obtain market approval, enriching the company's product pipeline in the ophthalmology field and enhancing market competitiveness

KHPG: Received the drug registration certificate for Lifi Shite eye drops

688799

688136

688382

688192

301015

36Kr learned that, as of the time of publication, the innovative drug concept has risen and then fallen, with Sinovac Biotech down over 10%, Baheal Medical and HWPC down over 7%, and companies like Xinlitai, KHPG, InventisBio, and Dizal Pharmaceutical also following the decline

36Kr

HWPC

SDKX

InventisBio

Dizal Pharmaceutical

Baheal Medical

Salubris

The innovative drug concept surged and then fell back, with Sinovac Biotech dropping over 10%

KHPG(002773.SZ)